Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C21H29NO2 |
| Molecular Weight | 327.4605 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1(C)C(C(=O)C2=CN(CCCCCO)C3=CC=CC=C23)C1(C)C
InChI
InChIKey=AFWBYMXUEMOBRP-UHFFFAOYSA-N
InChI=1S/C21H29NO2/c1-20(2)19(21(20,3)4)18(24)16-14-22(12-8-5-9-13-23)17-11-7-6-10-15(16)17/h6-7,10-11,14,19,23H,5,8-9,12-13H2,1-4H3
| Molecular Formula | C21H29NO2 |
| Molecular Weight | 327.4605 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: The description was created based on several sources, including
https://encrypted.google.com/patents/WO2006069196A1 | https://www.ncbi.nlm.nih.gov/pubmed/24014837
Curator's Comment: The description was created based on several sources, including
https://encrypted.google.com/patents/WO2006069196A1 | https://www.ncbi.nlm.nih.gov/pubmed/24014837
UR-144 N-5-Hydroxypentyl is a potent synthetic cannabinoid designed by Abbott Laboratories as a CB2 selective agonist for pain management. UR-144 N-5-Hydroxypentyl is a metabolite of another CB2-selective cannabinoid UR-144. Pre-clinical studies of nociceptive and neuropathic pain have shown that CB2-selective ligands are analgesics without causing the adverse side effects linked with CB1 receptor activation. However, nor UR-144 nor UR-144 N-5-Hydroxypentyl has no therapeutic application.
Originator
Approval Year
Sample Use Guides
FLIPR assays were performed using HEK cells stably coexpressing the chimeric GRq/o5 protein with the human CB2 receptor. Cells were seeded at 75 000 cells per well 1 day prior to the assay and assays performed with no-wash dye (FLIPR calcium assay kit, Molecular Devices, Sunnyvale, CA). Variable concentrations of compound 51 (UR-144 N-5-Hydroxypentyl) (0.3 nM to 10 μM), CP-55,940 (4) (at 10 μM final concentration) positive control, or vehicle negative control were added to cells in the presence of assay buffer (10 mM HEPES, pH 7.4, 130 mM NaCl, 5 mM KCl, 0.05% BSA), and fluorescence responses were measured immediately with a FLIPR machine. Net peak responses were compared with that of 10 μM CP-55,940 (4) and expressed as percentages of the CP-55,940 (4) evoked response.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:20:09 UTC 2023
by
admin
on
Sat Dec 16 11:20:09 UTC 2023
|
| Record UNII |
4MC625LVID
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
895155-95-0
Created by
admin on Sat Dec 16 11:20:10 UTC 2023 , Edited by admin on Sat Dec 16 11:20:10 UTC 2023
|
PRIMARY | |||
|
4MC625LVID
Created by
admin on Sat Dec 16 11:20:10 UTC 2023 , Edited by admin on Sat Dec 16 11:20:10 UTC 2023
|
PRIMARY | |||
|
11515395
Created by
admin on Sat Dec 16 11:20:10 UTC 2023 , Edited by admin on Sat Dec 16 11:20:10 UTC 2023
|
PRIMARY | |||
|
DTXSID801024750
Created by
admin on Sat Dec 16 11:20:10 UTC 2023 , Edited by admin on Sat Dec 16 11:20:10 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
|
||
|
|
TARGET -> AGONIST |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB2
EC50
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> METABOLITE |
XLR-11 was incubated with pooled human hepatocytes. Seven major metabolites were observed after 3-hr incubation.
IN-VITRO
Scientific Literature
|
||
|
PARENT -> METABOLITE ACTIVE |
Agonist of Human cannabinoid 1 & 2 receptors (CB1, CB2); Ki=680 nM (CB1), 0.71 nM(CB2)
IN-VITRO
Scientific Literature
|
